Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aurarix
- Development stage
- Preclinical
- Lead developer
- Cambium Bio
- Administration
- Ophthalmic
01
Overview
Aurarix is a biological therapeutic developed by Zheng Yang Biomedical Technology (ZYBT) for the treatment of dry eye disease. It is derived from human platelets and contains a concentrated mixture of growth factors, cytokines, and vitamins, including epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and platelet-derived growth factor (PDGF). These components work synergistically to promote the healing of the corneal epithelium, stabilize the tear film, and reduce ocular surface inflammation. Aurarix is typically prepared as an autologous or allogeneic serum-based eye drop, providing a regenerative approach to ocular surface disorders where standard artificial tears are insufficient.
- Brand names
- Aurarix
- Other names
- Platelet-derived eye dropsZYBT platelet lysate
02
Targets
EGFR (Epidermal growth factor receptor)PDGFR (PDGFR family)VEGFR (VEGFR family)TGFBR (TGF-beta receptor)FGFR (FGFR family)
Beyond the preview
Go deeper on Aurarix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurarix.